How do Innoviva, Inc. and Safehold Inc. compare by revenue?

Innoviva, Inc. reported revenue of $114.6M in Q4 FY2025, while Safehold Inc. reported $97.9M in Q4 FY2025. Innoviva, Inc. is 1.2× larger by last-quarter revenue.

Which is growing revenue faster, Innoviva, Inc. or Safehold Inc.?

Innoviva, Inc.'s latest revenue grew 24.8% year-over-year, versus 6.5% for Safehold Inc.. Innoviva, Inc. is growing faster on a YoY basis.

Which has a higher gross margin, Innoviva, Inc. or Safehold Inc.?

Innoviva, Inc.'s gross margin is 66.0% vs Safehold Inc.'s 98.6%. Safehold Inc. converts more of each revenue dollar into gross profit.

Which has a higher net margin, Innoviva, Inc. or Safehold Inc.?

Innoviva, Inc.'s net margin is 143.2% vs Safehold Inc.'s 28.5%. Innoviva, Inc. has the higher bottom-line margin.

What is the 2-year revenue CAGR for Innoviva, Inc. vs Safehold Inc.?

Over the trailing 8 quarters, Innoviva, Inc. compounded revenue at roughly 21.6% per year, versus 2.5% for Safehold Inc.. Innoviva, Inc. has the faster medium-term growth trajectory.

Where does this INVA vs SAFE data come from?

All figures are parsed directly from SEC EDGAR 10-Q / 10-K / 20-F / 6-K filings (for US-listed issuers) or EDINET filings (for Japanese issuers), then normalised into a common schema. Numbers update automatically as new filings are released.

vs

Side-by-side financial comparison of Innoviva, Inc. (INVA) and Safehold Inc. (SAFE). Click either name above to swap in a different company.

Innoviva, Inc. is the larger business by last-quarter revenue ($114.6M vs $97.9M, roughly 1.2× Safehold Inc.). Innoviva, Inc. runs the higher net margin — 143.2% vs 28.5%, a 114.7% gap on every dollar of revenue. On growth, Innoviva, Inc. posted the faster year-over-year revenue change (24.8% vs 6.5%). Over the past eight quarters, Innoviva, Inc.'s revenue compounded faster (21.6% CAGR vs 2.5%).

Innoviva, Inc.INVAEarnings & Financial Report

Nasdaq · Health Care · Pharmaceutical Preparations

Innoviva, Inc. is a healthcare company specializing in the development, commercialization, and royalty management of prescription therapeutics for respiratory diseases, infectious diseases, and critical care conditions. It partners with leading global pharmaceutical firms to deliver treatments for asthma, COPD and other chronic illnesses to patients across core markets including North America and Europe.

Safehold Inc.SAFEEarnings & Financial Report

NYSE · Financials · Real Estate Investment Trusts

SAFE Investment Company Limited is a Chinese sovereign wealth fund based in Hong Kong.

INVA vs SAFE — Head-to-Head

Bigger by revenue

INVA

1.2× larger

$114.6M

$97.9M

Growing faster (revenue YoY)

INVA

+18.3% gap

24.8%

6.5%

Higher net margin

INVA

114.7% more per $

143.2%

28.5%

Faster 2-yr revenue CAGR

INVA

Annualised

21.6%

2.5%

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric	INVA	SAFE
Revenue	$114.6M	$97.9M
Net Profit	$164.2M	$27.9M
Gross Margin	66.0%	98.6%
Operating Margin	34.0%	27.4%
Net Margin	143.2%	28.5%
Revenue YoY	24.8%	6.5%
Net Profit YoY	707.4%	7.1%
EPS (diluted)	$2.19	$0.38

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue

INVA

SAFE

Q4 25	$114.6M	$97.9M
Q3 25	$107.8M	$96.2M
Q2 25	$100.3M	$93.8M
Q1 25	$88.6M	$97.7M
Q4 24	$91.8M	$91.9M
Q3 24	$89.5M	$90.7M
Q2 24	$99.9M	$89.9M
Q1 24	$77.5M	$93.2M

Net Profit

INVA

SAFE

Q4 25	$164.2M	$27.9M
Q3 25	$89.9M	$29.3M
Q2 25	$63.7M	$27.9M
Q1 25	$-46.6M	$29.4M
Q4 24	$20.3M	$26.0M
Q3 24	$1.2M	$19.3M
Q2 24	$-34.7M	$29.7M
Q1 24	$36.5M	$30.7M

Gross Margin

INVA

SAFE

Q4 25	66.0%	98.6%
Q3 25	70.1%	98.5%
Q2 25	82.9%	99.1%
Q1 25	82.7%	98.8%
Q4 24	85.1%	98.8%
Q3 24	81.6%	98.8%
Q2 24	85.1%	98.8%
Q1 24	77.5%	98.8%

Operating Margin

INVA

SAFE

Q4 25	34.0%	27.4%
Q3 25	32.1%	25.9%
Q2 25	48.6%	25.5%
Q1 25	46.7%	25.9%
Q4 24	47.0%	24.6%
Q3 24	48.3%	17.5%
Q2 24	54.7%	26.7%
Q1 24	33.3%	26.4%

Net Margin

INVA

SAFE

Q4 25	143.2%	28.5%
Q3 25	83.4%	30.5%
Q2 25	63.5%	29.8%
Q1 25	-52.6%	30.1%
Q4 24	22.1%	28.3%
Q3 24	1.4%	21.3%
Q2 24	-34.7%	33.0%
Q1 24	47.1%	33.0%

EPS (diluted)

INVA

SAFE

Q4 25	$2.19	$0.38
Q3 25	$1.08	$0.41
Q2 25	$0.77	$0.39
Q1 25	$-0.74	$0.41
Q4 24	$0.43	$0.36
Q3 24	$0.02	$0.27
Q2 24	$-0.55	$0.42
Q1 24	$0.46	$0.43

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric	INVA	SAFE
Cash + ST InvestmentsLiquidity on hand	$550.9M	$21.7M
Total DebtLower is stronger	—	$4.6B
Stockholders' EquityBook value	$1.2B	$2.4B
Total Assets	$1.6B	$7.2B
Debt / EquityLower = less leverage	—	1.90×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments

INVA

SAFE

Q4 25	$550.9M	$21.7M
Q3 25	$476.5M	$12.1M
Q2 25	$397.5M	$13.9M
Q1 25	$319.1M	$17.3M
Q4 24	$305.0M	$8.3M
Q3 24	$260.6M	$15.6M
Q2 24	$217.0M	$13.4M
Q1 24	$178.4M	$11.3M

Total Debt

INVA

SAFE

Q4 25	—	$4.6B
Q3 25	—	$4.5B
Q2 25	—	$4.4B
Q1 25	—	$4.3B
Q4 24	—	$4.3B
Q3 24	—	$4.3B
Q2 24	—	$4.2B
Q1 24	—	$4.1B

Stockholders' Equity

INVA

SAFE

Q4 25	$1.2B	$2.4B
Q3 25	$1.0B	$2.4B
Q2 25	$714.8M	$2.4B
Q1 25	$646.9M	$2.4B
Q4 24	$691.2M	$2.3B
Q3 24	$668.5M	$2.3B
Q2 24	$665.5M	$2.3B
Q1 24	$703.7M	$2.3B

Total Assets

INVA

SAFE

Q4 25	$1.6B	$7.2B
Q3 25	$1.4B	$7.1B
Q2 25	$1.3B	$7.1B
Q1 25	$1.3B	$6.9B
Q4 24	$1.3B	$6.9B
Q3 24	$1.2B	$6.8B
Q2 24	$1.2B	$6.8B
Q1 24	$1.3B	$6.7B

Debt / Equity

INVA

SAFE

Q4 25	—	1.90×
Q3 25	—	1.89×
Q2 25	—	1.87×
Q1 25	—	1.85×
Q4 24	—	1.84×
Q3 24	—	1.88×
Q2 24	—	1.81×
Q1 24	—	1.81×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric	INVA	SAFE
Operating Cash FlowLast quarter	$54.5M	$47.8M
Free Cash FlowOCF − Capex	—	—
FCF MarginFCF / Revenue	—	—
Capex IntensityCapex / Revenue	—	—
Cash ConversionOCF / Net Profit	0.33×	1.72×
TTM Free Cash FlowTrailing 4 quarters	—	—